Physiologic and Symptomatic Responses to Low-Level Substances in Individuals with and without Chemical Sensitivities: A Randomized Controlled Blinded Pilot Booth Study by Joffres, Michel R. et al.
1178 VOLUME 113 | NUMBER 9 | September 2005 • Environmental Health Perspectives
Research
Despite the controversial nature of multiple
chemical sensitivities (MCS)/environmental
sensitivities (ES), the following consensus crite-
ria (Bartha et al. 1999) have been proposed to
define MCS/ES: The symptoms are repro-
ducible with repeated chemical exposure; the
condition is chronic; low levels of exposure
(lower than previously tolerated) result in man-
ifestations of the syndrome; the symptoms
improve or resolve when the incitants are
removed; responses occur to multiple chemi-
cally unrelated substances; and symptoms
involve multiple organ systems. These criteria
are based upon previous definitions (Cullen
1987; Nethercott et al. 1993; Randolph 1961).
Some researchers consider another term,
“idiopathic environmental intolerances” (IEI),
more appropriate [International Programme
on Chemical Safety (IPCS) 1996] and believe
it should be restricted to individuals with
absolutely no abnormalities except a self-
reported abhorrence to chemicals. Many people
with chemical sensitivities have other conditions
and symptoms such as asthma, rhinosinusitis,
dermatitis, and headaches triggered by chemical
exposures and would not meet this restrictive
deﬁnition of idiopathic environmental intoler-
ances. Our previous study (Joffres et al. 2001)
identiﬁed a common set of consistent symp-
toms that follow exposure: difﬁculty in concen-
trating, fatigue, forgetfulness, irritability, itchy
or burning eyes, sneezing, and hoarseness or loss
of voice. The prevalence of ES is not negligible
(Kreutzer et al. 1999; Meggs et al. 1996), and
physicians, even those most familiar with
these conditions, often overlook such a syn-
drome (Kutsogiannis and Davidoff 2001).
Questions remain unanswered regarding the
etiology, associated mechanisms, and incon-
sistency in pattern of symptoms. Several
reports (Fiedler and Kipen 1997; Kipen and
Fiedler 2002a, 2002b; Sparks et al. 1994)
have outlined some of the different viewpoints
on etiology and physiopathology. Meggs
(1995) and Bascom et al. (1997) have pro-
posed a neurogenic inflammation model.
Sensitization or kindling of olfactory-limbic
pathways by acute or chronic exposure has
also been proposed (Bell et al. 1997, 1999;
Miller 2001). Researchers for the IPCS (1996)
proposed that 
the key experiment is to determine in a double-
blind challenge study whether subjects with “IEI”
successfully discriminate between exposures to
environmental factors (including to which illness is
attributed) and placebo. If the subjective response
(appearance of symptoms) of test subjects is able to
discriminate between exposure to test chemicals
and placebos, in a blinded design, this would sug-
gest the operation of a toxicological mechanism in
which culpable agents interact with tissue targets to
trigger a receptor-mediated pathophysiological
response.
A few studies have attempted to look at
experimental testing of affected individuals
(Fiedler et al. 2000; Fiedler and Kipen 2001;
Rea et al. 1991; Staudenmayer et al. 1993).
A critical factor that may have been over-
looked in some of these studies is the adapta-
tion of subjects to baseline study protocols.
Adaptation is deﬁned here as the period taken
by the subjects in a study to get used to the
general study protocols, obtaining stable
physiologic (i.e., skin conductance and symp-
tomatic) readings before the actual introduc-
tion of substances. We realized that with our
patient population expressing a high level of
reactivity, we would need to get stable read-
ings before introducing any test substance.
Otherwise, we might obtain erratic physio-
logic or symptomatic responses because of
testing conditions, which would make it
impossible to differentiate challenge sub-
stances from placebos. Surprisingly, we have
not found any psychophysiologic literature
discussing the importance of stabilizing read-
ings before starting experiments other than
the usual caution of a few minutes of relax-
ation. Most studies have either used a set
period for adaptation (Fiedler et al. 2000) or
not considered this factor at all (Staudenmayer
et al. 1993).
Therefore, we hypothesized that individu-
als with ES may require more time to adapt to
the experimental conditions compared with
controls without chemical sensitivities. Also,
we hypothesized that each individual may
have a different adaptation period. We also
wanted to explore the type of measure that
would be the most useful to detect change and
therefore included several psychophysiologic
measures.
Addressing the issue of symptom develop-
ment has also been critical to research on these
illnesses. There is a need to see how symptoms
develop and what triggers are associated with
symptoms in individuals with ES. Is there a
relation between symptoms and skin conduc-
tance response during exposure to chemicals?
Address correspondence to M. Joffres, Nova Scotia
Environmental Health Centre, 3064 Lake Thomas
Dr., Fall River, NS B2T 1K6 Canada. Telephone:
(902) 860-3069. Fax: (902) 860-2046. E-mail:
mjoffres@sfu.ca
This study was supported by the Nova Scotia
Department of Health.
The authors declare they have no competing
ﬁnancial interests.
Received 21 April 2004; accepted 19 May 2005.
Physiologic and Symptomatic Responses to Low-Level Substances in
Individuals with and without Chemical Sensitivities: A Randomized
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We conducted a pilot study using a randomized, single-blind, placebo-controlled exposure among
10 individuals with and 7 without reported chemical sensitivities in a dedicated testing chamber.
Objectives of the study were to explore the length of the adaptation period to obtain stable read-
ings, evaluate responses to different substances, and measure the level and type of symptomatic
and physiologic reactions to low-level exposures. Reported and observed symptoms, electrodermal
response, heart rate, skin temperature, surface electromyogram, respiratory rate, contrast sensitiv-
ity, and the Brown-Peterson cognitive test were used and compared between cases and controls
and between test substances (glue, body wash solution, dryer sheet) and control substances
(unscented shampoo and clean air). Subjects with chemical sensitivities (cases) took longer to
adapt to baseline protocols than did controls. After adaptation, despite small study numbers, cases
displayed statistically signiﬁcant responses (all measures, p < 0.02) in tonic electrodermal response
to test substances compared with controls and compared with the control substance. Symptoms
were also higher in cases than in controls for the body wash solution (p = 0.05) and dryer sheets
(p = 0.02). Test–retest showed good agreement for both symptoms and tonic electrodermal
responses (McNemar’s test, p = 0.32 and p = 0.33, respectively). Outside of skin conductance,
other measures had no consistent patterns between test and control substances and between cases
and controls. This study shows the importance of using an adaptation period in testing individuals
with reported chemical sensitivities and, despite small numbers, raises questions about underlying
mechanisms and level of reactivity to low-level chemical exposures in sensitive individuals.
Key words: complex mixtures, electrodermal response, multiple chemical sensitivity, pilot project,
randomized controlled trial, skin conductance. Environ Health Perspect 113:1178–1183 (2005).
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controls to the substances was another major
objective of this pilot study.
Hence, to answer these questions, we
conducted a pilot, blinded, controlled booth
study at the Nova Scotia Environmental
Health Centre, a government-funded facility
dedicated to research and management of
individuals with ES.
Materials and Methods
Inclusion criteria. Subjects with sensitivities
were selected from the last 50 new patients
enrolled at the Nova Scotia Environmental
Health Centre who fulfilled the consensus
criteria (Bartha et al. 1999) and who gave
informed consent to participate in the study.
The Dalhousie University Health Sciences
Human Research Ethics Board approved the
study protocol. Controls, without known
chemical sensitivities, were recruited from
friends of the patients and from advertise-
ment in local churches.
Exclusion criteria. Subjects were excluded
from the study if they had any other major ill-
nesses such as cancer (outside of skin cancer
or past cancer without relapse in the preced-
ing 5 years), insulin-dependent diabetes, stage
2 or 3 hypertension (systolic/diastolic blood
pressure: stage 2, 160–179/100–109; stage 3,
> 180/> 110), history of myocardial infarc-
tion, angina pectoris, stroke, or psychiatric
disorders such as major depressive disorder,
schizophrenia, shared psychotic disorder,
dementia, or drug dependence.
A total of 12 cases (all women; mean
age, 40 years; range, 25–60 years) and 7 con-
trols (all women; mean age, 42 years; range,
26–59 years) gave an informed consent to
participate and fulfilled the initial inclusion/
exclusion criteria of the study. The subjects
were matched within age, education, and eth-
nicity categories.
Challenge booth. The study was con-
ducted in a dedicated room that included the
challenge booth (Figure 1) made from inert
materials with no apparent odors, allowing
introduction of materials that release various
chemicals into the environment. The booth is
a glass room with steel framing with dimen-
sions of 2.2 m (7.2 ft) in height by 1.2 m
(4 ft) in width by 1.8 m (6 ft) in depth. The
construction materials and procedure used
have received careful consideration toward
making it suitable for research work on indi-
viduals with chemical sensitivities. The air-
ﬂow, temperature, and lighting in the facility
can be varied to increase the comfort level of
the subjects. A side box attached to the booth
was used to introduce chemicals into the air
stream. The door to the side box opens on
one side of the booth so the subjects are
unaware of the substance being introduced
into the booth. Air is allowed to enter the side
box into an inlet provided on the frosted side
of the booth. The inlet height is at the breath-
ing level of the occupant. The air entering the
booth is 100% outdoor air that has been ﬁl-
tered before being distributed throughout the
clinic, not recirculated, and is then directly
vented to the outdoors through an exhaust
located in the ceiling of the booth.
Test substances. Test substances for the
study were those commonly reported by
affected people to cause reactions: common
glue, a scented body wash solution, dryer
sheet, and for control substances, unscented
shampoo and clean air. These substances were
contained in a closed metal box, introduced
through the side box, and passively released in
the booth airﬂow. A new dryer sheet was used
for each session. Patients could not smell the
substance because of nose plugs.
Outcome measures. Before and after each
booth session, subjects answered a symptom
questionnaire on symptoms reported by
Joffres et al. (2001; e.g., eye irritation, throat
irritation, sleepiness, headache) as the top
symptoms experienced by our patient popu-
lation after an exposure. The questionnaire
measured irritation on an ordinal scale of
0–10, with 0 being barely detectable and 10
being strongest detectable (Joffres et al. 2001).
The booth environment (light, sound, and
temperature) was also rated before and after
each session on a scale of 0–10 (0 = poor, 10 =
excellent). The purpose of the adaptation ses-
sions was to reduce the number and severity of
symptoms reported to the nurse among reac-
tive subjects. The adaptation sessions identi-
ﬁed symptomatic responses shown by subjects
to the baseline protocols of the study such as
wearing nose plugs, wearing respiratory belt,
and the other BIOPAC (BIOPAC Systems
Inc., Goleta, CA, USA) measures.
During the testing period, we compared
pre- and postsymptom scores from that day,
and coded any change in score or type of
symptom as a positive response. We disre-
garded the symptoms that occurred consis-
tently during the adaptation sessions (baseline
symptomatic responses) while computing a
response toward challenge substances.
After the booth session, subjects recorded
and reported to the nurse any changes they
observed during the next 8-hr period. They
were instructed not to visit malls or other sim-
ilar places where they may be exposed to other
substances 8 hr before and 8 hr after each
booth session. Because many of our patients
reported effects lasting up to 4 or 5 days after
a booth session, subjects were exposed to only
one substance at a time and had a minimum
of 1 week between two booth sessions.
We used the Brown-Peterson test (Peterson
and Peterson 1962) to test a variation in the
short-term memory span of the subjects after a
booth exposure. Subjects were given a series
of trigrams of letters; each trigram was fol-
lowed by a number countdown challenge,
after which subjects were asked to recall the
trigram. Short-term memory for 9, 18, and
36 sec intervals was examined. The test was
conducted before and after each exposure
session.
Contrast sensitivity (Schreiber et al. 2002),
which provides a detailed assessment of spatial
vision and is sometimes recommended as a test
to screen visual damage caused by chemical
exposures such as solvents, was tested before
and after each session. Peak ﬂow was used as a
pre- and postsession measure to determine
impairment in lung function. All these meas-
ures were recorded pre- and postsession during
all booth sessions for each subject.
Physiologic measures. To assess physio-
logic measures of skin temperature, skin con-
ductance, respiratory rate, heart rate, and
surface electromyography (EMG), we used
used the BIOPAC MP 100 data acquisition
system (BIOPAC Systems Inc.) during each
booth session. Surface EMG was collected at
a rate of 1,000 samples/sec using the Biopac
electrodes placed at the upper trapezius mus-
cle. Disposable electrocardiogram electrodes
were used to acquire heart rate at a sampling
rate of 1,000 samples/sec. The positive elec-
trode was placed on the right wrist, the nega-
tive on the left wrist, and the ground electrode
on the right ankle. Finger temperature and
skin conductance were measured at a rate of
3 sample/sec.
Of the physiologic measures, only skin
conductance was a consistent indicator of
adaptation and response to challenge sub-
stances postadaptation. Results and discussion
in this article are therefore restricted to this
physiologic measure.
Skin conductance recording and analysis.
We recorded skin conductance using Ag/AgCl
electrodes ﬁlled with isotonic electrolyte jelly
and attached to the fore and middle ﬁngers of
the left hand. Subjects were asked to wash their
hands with lukewarm water before the start of
each booth session. Skin conductance data
acquisition and analysis were conducted using
Acknowledge 3.2.4 software (BIOPAC
Systems Inc.). The raw data collected were ﬁrst
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Figure 1. Challenge booth and testing conditions.smoothed using low-pass ﬁlter. The readings
were compared with the baseline readings from
that day.
Skin conductance response has been
described in the literature as having two com-
ponents: phasic and tonic responses (e.g., Lim
et al. 1997). Phasic responses may be evoked
even by a discrete stimulus such as subtle
variations in environment or even thought
processes. Tonic skin conductance response is
the baseline level of skin conductance in the-
absence of any stimulus. This is known to
vary with time in the presence of a stimulus
depending upon the psychological state of the
individual and their autonomic regulation.
We considered only the tonic responses while
assessing a positive response to challenge sub-
stances in our pilot study. Recordings showed
variations in the level of conductance because
of artifacts or other factors, and the change in
amplitude and the length of the tonic response
cannot be easily used in a continuous form
without arbitrary criteria about where and
how the measures will be made. Therefore, we
adopted a simple criterion that could be easily
reproduced: Tonic responses were considered
positive if there was a change in amplitude
from the preexposure period (of the session)
by at least 0.5 microsiemens (µS) about 20 sec
after the introduction of the substance.
Booth session protocol. In an orientation
visit we discussed details of the study with the
subjects and answered questions about the
study. After consent, an adaptation period
allowed subjects to get used to baseline study
protocols, such as cognitive testing (Brown-
Peterson test), answering questionnaires, getting
used to the booth, and wearing nose plugs.
Each subject was given up to 10 individual
booth sessions with a maximum of four ses-
sions for adaptation to the baseline study pro-
tocols. Each booth session consisted of the
same set of changes occurring at the same
time, which included opening and closing of
the side door through which substances could
be introduced (2.5, 5, and 10 min), exhaust
fan going on low speed (7 min), high speed
(11.5 min), and then being turned off
(12.5 min) (Figure 2). The stability in read-
ings was judged only by the stability of tonic
skin conductance responses (see above for
criteria) and in reduction of symptomatic
responses (symptom scores) based on the
interview with the nurse.
After adaptation, the subjects were blindly
challenged to the test substances, clean air,
glue, body wash solution, and dryer sheet in
a randomized sequence. Subjects received
test substances only if an “open and close”
door sequence (time, 2.5 min) in the pretest
period, also done during the adaptation phase,
did not elicit any change in conductance
greater than our defined threshold of 0.5 µS
approximately 20 sec after the introduction of
the substance. The subjects received only one
challenge substance (placebo, control, or test
substances) in a session. Each subject was
retested to at least one substance that they
reacted to in a randomized sequence. Even if
they did not react to any substance (as in the
case of our control subjects), they were still
retested on at least one substance to conﬁrm
their nonreactivity.
Of the 12 subjects with ES, two did not
adapt to the baseline protocols and were
excluded from further study. All seven con-
trols completed the adaptation phase and
were able to participate in the next phase of
the study (Figure 3).
This pilot study was single blinded. Subjects
were not aware of what substance was intro-
duced and could not smell the substance
because of nose plugs. The nurse monitoring
subjects was not aware of what was being intro-
duced into the booth. The researcher introduc-
ing the substance also monitored data recording
and analyzed the results and was separated from
the nurse and the subject by a partition. The
order of administration of the three test sub-
stances (glue, body wash lotion, dryer sheet) and
a control substance (unscented shampoo) was
randomized using a table of random numbers.
Data analyses. Heart rate variability
was analyzed by the Institute of Heart Math
(McCraty et al. 1995) and did not differ
between test and control substances or between
patients and controls. Respiratory rate showed
erratic patterns that seemed to be inﬂuenced by
presence of the nose plug, and we could not
identify any speciﬁc patterns.
In addition to skin conductance, symptom
scores before and after booth sessions were the
only other measure that indicated completion of
an adaptation period and responses to challenge
period. No other measures are discussed in this
article. Data were dichotomized into reaction
versus no reaction to simplify presentation and
allow the study to be easily reproduced.
We used SAS (version 9.1; SAS Institute
Inc., Cary, NC, USA) for the statistical analy-
ses. Fisher’s exact test statistic (two sided) was
used to test differences in proportion using an
alpha level of 0.05 between cases and controls,
and McNemar’s statistic was used for paired
data (between placebo and substance among
cases and among controls). Because one col-
umn in the 2 × 2 table had 0 frequencies, we
used a frequency of 0.001 to be able to esti-
mate a p-value.
Results
Table 1 presents the measures that were col-
lected during the booth sessions, and Figure 2
shows the timeline for the different sequences
of the preexposure, exposure period, and post-
exposure period.
Figure 3 shows skin conductance responses
of cases and controls to baseline study proto-
cols. The proportion of cases reacting to the
different testing conditions (different sounds)
using set criteria described above decreased
with the number of sessions and was much
higher in cases than in controls. In the ES
group, 83% (10 of 12) adapted after four ses-
sions, whereas 17% (2 of 12) did not adapt
after four sessions. Most of the controls adapted
in a single session (86%, 6 of 7).
Joffres et al.
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Figure 2. Time line for booth session. Sequence of
changes: 1 and 2, opening and closing of side door
of booth; 3, exhaust fan on low speed; 4, opening
and closing of side door of booth; 5, exhaust fan on
high speed; 6, exhaust fan off.
Figure 3. Number of sessions required for each individual to reach stable baseline skin conductance readings
(adaptation) among (A) cases and (B) controls. Subjects 3 and 9 (black bars) did not adapt after four sessions.
Table 1. Booth sessions measures.
Before During After
Interview with nurse Skin conductance Interview with nurse
Peak ﬂow Skin temperature Peak ﬂow
Contrast sensitivity EMG Contrast sensitivity
Brown-Peterson test Respiratory rate Brown-Peterson test
Symptoms rating Electroencephalogram Symptoms rating
Environment rating Nurse’s observation Environment ratingAn example of a tonic skin conductance
response during the adaptation period is pre-
sented in Figure 4 by stimuli and by session.
Although there were variations in skin con-
ductance after the different stimuli in the ﬁrst
and second sessions (first and second win-
dow), there were no longer tonic responses in
the third session. Figure 5 presents the per-
centage of individuals with ES having a spe-
cific symptomatic response to each of three
challenge substances: glue, body wash solu-
tion, and dryer sheet. The most common type
of reaction was burning eyes and headaches
after exposure to the dryer sheet and glue.
The percentages of cases and controls pre-
senting a skin conductance response or any
specific symptom to the test substance are
shown in Figure 6. The level of response was
higher for all test substances in cases than in
controls and higher for test substances (glue
and dryer sheet) than for control substances
(unscented shampoo and clean air) in cases.
There was a relatively close match between
physiologic and symptomatic responses dur-
ing exposure to challenge substances. Only
one control displayed a response in skin con-
ductance to a test substance, and two controls
showed symptom responses to test substances;
none showed symptom responses to the con-
trol substances.
The most significant difference in skin
conductance between cases and controls was
for dryer sheets (p < 0.0001), followed by glue
(p = 0.0004) and body wash solution (p =
0.02). In cases, comparing skin conductance
between substances and control substances,
there were similar patterns showing statistical
differences between control substance and
dryer sheets (p = 0.0007), glue (p = 0.006),
and body wash solution (p = 0.02).
For symptomatic responses, there were no
statistically signiﬁcant differences among cases
between any substances and the control sub-
stances, but there were statistically signiﬁcant
differences between cases and controls for the
dryer sheet (p = 0.02) and for glue (p < 0.05).
There were no statistically significant differ-
ences among controls.
Table 2 shows symptomatic and skin con-
ductance test–retest results in selected cases and
controls by subject and by substance. Table 3
presents all our test–retest data on selected indi-
viduals. There was an overall good agreement
between test and retest for both symptoms and
skin conductance responses (McNemar’s test,
p = 0.32 and p = 0.33, respectively).
Discussion
The purpose of this pilot study was to shed
some light on the experimental conditions,
substances, and measures that could lead to
better trials in chemically sensitive individuals.
There was a clear difference in the time taken
by cases to adapt to the experimental condi-
tions, and two cases did not adapt after four
sessions; however, more than half adapted
after the second session, and six of seven con-
trols adapted in only one session. We have not
found any data that emphasize the need for an
adaptation period in studies that are measur-
ing physiologic responses outside of the few
minutes used to stabilize readings. There is
also no mention of the importance of stabiliz-
ing the reactions to the experimental con-
ditions such as being observed, changes in
temperature and airﬂow, and sounds such as
opening and closing a door to introduce a sub-
stance. Although adaptation may not be an
important issue in “normal” people, it is cer-
tainly an issue in people with ES who are usu-
ally in a state of hyper-reactivity. Reactions to
test substances need to be differentiated from
the effect of the experimental conditions.
Otherwise, the experimental “noise” will result
in misclassiﬁcation, reducing statistical signiﬁ-
cance and resulting in negative ﬁndings.
Because we removed most of the noise due
to the experimental conditions, the ability of
individuals to detect the test substances, com-
pared with placebo and compared with con-
trols, raises several questions. First, EMG, heart
rate, respiratory rate, skin temperature, cogni-
tion, and contrast sensitivity did not show any
consistent patterns of reaction. Therefore, these
measures may not be very sensitive or relevant
to the pathophysiology of reactions in individ-
uals with ES. Because this was a pilot study,
a larger sample size might have shown some
more subtle differences, and therefore we can-
not totally reject the usefulness of these meas-
ures in their ability to discriminate between
test and control substances.
Second, differences in skin conductance
response bring into question what type of reac-
tion takes place after exposure to a very low-
level substance. Skin conductance responses
have been widely used in the psychosocial ﬁeld.
Since the work of Edelberg (1972), research
Booth study of environmental sensitivities
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Figure 4. Example of tonic skin conductance
responses observed in a case during adaptation,
by stimuli and by session. Sequence of changes:
1 and 2, opening and closing of booth side door;
3, exhaust fan on low speed; 4, opening and closing
of booth side door; 5, exhaust fan on high speed;
6, exhaust fan off.
Figure 5. Percentage of individuals with ES pre-
senting responses to challenge substances, by
type of symptom and substance (sub).
Figure 6. Percentage of (A) cases and (B) controls presenting skin conductance or any symptom response
by test substance. Placebo was clean air. Abbreviations: BWS, body wash solution; CS, control substance;
DS, dryer sheet.has shown that changes in skin conductance
(or, conversely, resistance) are affected by the
ﬁlling of sweat ducts and the number of sweat
glands affected. This mechanism, under the
autonomic nervous system control, seems
cholinergic, regulated by the premotor cortex,
the hypothalamus and limbic systems, and the
reticular formation. The role of the hypothala-
mus/limbic system has been previously sug-
gested in the pathophysiology of MCS (Bell
et al. 1997). Nevertheless, as Bell and col-
leagues pointed out, there have been no con-
trolled experiments to determine whether or
not sensitization to low-level chemical expo-
sures occurs in MCS patients.
Third, because the hypothalamus/limbic
system is closely linked with emotions, is it
possible that the perception of chemicals
through the eyes (Millqvist et al, 1999) or the
upper respiratory system (Shusterman 2002)
provoked a rise in anxiety, activating the auto-
nomic nervous system, resulting in a skin con-
ductance response? In future experiments, we
will be studying patterns of reactions to see if
we can differentiate anxiety responses from the
type of response observed in this study.
Fourth, in contrast to a pure anxiety
response hypothesis, it could be argued that
irritation of these chemosensitive structures
(eyes and respiratory tract) could lead to neuro-
genic inﬂammation as hypothesized by Meggs
(1995) and Bascom et al. (1997). Stimulation
of the glossopharyngeal and vagal nerves via
the hypopharynx and larynx could result in the
type of symptoms described by patients and
the observer. Most cases reported burning eyes,
eye irritation, headaches, or sleepy or drowsy
feelings, which ﬁt with our previous study of
symptoms after exposure in chemically sensi-
tive patients (Joffres et al. 2001).
Some of our patients were not able to
adapt to baseline protocols, showing erratic
responses to the testing conditions. These sub-
jects are therefore in a state of hyperreactivity
and should not be included in such experi-
ments. Some cases reacted to the unscented
shampoo control substance, but none reacted
to clean air. This suggests that clean air should
be used as the control substance.
In subjects who adapted to the experimen-
tal setup, the most irritant substances (dryer
sheets and glue) triggered a physiologic (skin
conductance) response accompanied with
symptomatic responses in many cases (Figure
6). When we looked at whether symptoms
preceded or followed the skin conductance
reaction, we found that most symptoms
occurred at the same time or followed rather
than preceded electrodermal response. Only
20% of subjects had symptoms preceding
changes in skin conductance.
Several studies have shown that undetected
chemicals can still induce brain activations
(Lorig 1994; Sobel et al. 1999). Staudenmayer
et al. (1993) used an olfactory masker with the
test substances and as a control substance.
Therefore, if the olfactory masker is not per-
ceived by the sense of smell but is still able to
alter neurophysiology, there should be no
detectable differences between test and control
substance (olfactory masker) because of the
added noise of the olfactory masker. If patients
had adapted to the olfactory masker, they
might have been able to detect a difference, but
the study protocol did not take this problem
into account. Lorig (1994) and Sobel et al.
(1999) also raised the question of why our
controls did not detect the active substances.
Perhaps they did not because we considered
only tonic skin conductance responses in our
study. All but one of our control subjects dis-
played only phasic responses, whereas almost
all the cases showed tonic variations. We will
be looking at the importance of phasic changes
in our next study. In addition, we did not use
measures as sensitive as the electroencephalo-
gram. The pilot study has also helped us
identify skin conductance ranges in which
a specific type of response, phasic or tonic,
is displayed if a stimulus is perceived as a
Joffres et al.
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Table 2. Symptomatic and skin conductance test–retest results in selected cases and controls by subject
and by substance.
Case/ Test Retest Test skin Retest skin
control symptom symptom Substance conductance conductance
Case 1 1 Glue 1 1
Case 1 1 Glue 1 1
Case 1 1 Glue 0 (EMG) 1 (EMG)
Case 0 1 Glue 1 (EMG) 0 (EMG)
Case 1 1 Glue 1 1 (EMG)
Case 0 0 Body wash 1 1
Case 1 1 Body wash 1 0 (EMG)
Case 0 0 Body wash 1 1
Case 1 1 Dryer sheet 1 1 (SKT)
Case 1 1 Dryer sheet 1 1
Case 1 1 Dryer sheet 1 1
Case 0 0 Dryer sheet 1 1 (EMG)
Case 0 0 Placebo 0 0
Case 0 0 Placebo 0 0
Case 0 0 Placebo 0 0
Case 0 1 Control 1 1
Case 1 1 Control 1 0 (EMG)
Case 1 1 Control 0 0
Case 1 1 Control 0 0
Case 0 0 Control 0 0
Control 1 0 Glue 0 0
Control 1 0 Glue 0 0
Control 0 0 Glue 0 0
Control 1 1 Body wash 1 1
Control 0 0 Body wash 0 0
Control 1 0 Dryer sheet 0 0
Control 0 0 Dryer sheet 0 0
Control 0 0 Dryer sheet 0 0
Control 0 0 Control 0 0
Control 0 0 Placebo 0 0
Control 0 0 Placebo 0 0
Abbreviations: 0, no response; 1 positive response; EMG, positive response by EMG; SKT, positive response by skin
temperature.
Table 3. Examples of test and retestskin and symptomatic responses for selected substances.
Skin conductance Symptomsa
Test Retest Test Retest
Subject Test substance L A L A Symptom Scores Symptom Scores
1 Glue 210 1.00 600 0.95 Eye irritation 0–7 Ear pain 0–6
Nausea 1–6
2 Glue 253 0.86 265 1.38 Eye irritation 0–5 Headache 0–5
Tired 1–7 Tired 2–7
3 Dryer sheet 300 1.20 500 0.90 Tired 1–8 Tired 0–6
4 Dryer sheet 246 0.90 169 0.98 Headache 3–9 Burning eyes 0–5
5 Body wash 302 0.83 412 0.95 Eye irritation 0–7 Tired 1–6
6 (control) Body wash 256 1.03 425 1.4 Fatigue 3–9 Fatigue 0–8
7 Control 462 0.95 509 0.86 None Throat irritation 1–7
Brain fog 2–8
8 Control 324 1.05 — — Brain fog 1–6 Clumsiness 0–7
Abbreviations: —, no data; A, amplitude in microsiemens of tonic skin conductance responses; L, latency in seconds.
aReported symptoms and symptom severity scores before and after introduction of test substance.Booth study of environmental sensitivities
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stressor. This will be critical for such studies
because these ranges will help us identify what
type of response can be considered given a spe-
ciﬁc range of baseline. We will be conﬁrming
this with a larger sample size.
Reaction times varied by substance and
were fastest with the dryer sheet, where most of
the individuals (8 of 10) reacted in < 200 sec
after the introduction of the substance. It is
therefore important to allow enough time
to observe a response and not introduce other
substances that could create experimental
noise. Introducing more than one challenge
substance in one session, sham exposures,
or maskers may not allow isolation of the
delayed responses that we observed in a few
cases for substances other than the dryer sheet.
Test–retest performed on ﬁve cases react-
ing to glue showed that in four cases the level
of reaction was higher in the retest session
(similar trends were also observed while retest-
ing on two other test substances), and this ﬁts
with Bell et al.’s (1997, 1999) theory regard-
ing sensitization of olfactory-limbic pathways
and what Sorg and Newlin (2002) observed in
rats, where repeated chemical exposure pro-
duced sensitization of the central nervous sys-
tem circuitry. What was also interesting in the
Sorg and Newlin (2002) study was that rats
given repeated formaldehyde demonstrated
increased fear conditioning to odor paired
with footshock, suggesting amplification of
neural circuitry guiding fear responding to a
conditioned odor cue.
Therefore, whether or not these reactions
are triggered by an unconscious anxiety
response after the awareness by the nervous
system of a situation perceived as threatening
can still be argued. We tend to agree with
Spurgeon (2002) that the reporting of symp-
toms may result from a complex set of interac-
tions between aspects of personality, attitudes,
culture, and social climate as well as any patho-
logic changes. Fiedler et al. (2000) noted that
reactions to speciﬁc substances in individuals
do not necessarily elicit physiologic responses.
We noted this in a few cases in our study as
well. The fact that, in other cases, the physio-
logic reaction was not followed by any sympto-
matic response raises the question of whether
an anxiety response, recorded at the uncon-
scious level, could still result in such an isolated
physiologic reaction.
Symptomatic responses in sensitive indi-
viduals and not in controls also correspond to
Fiedler et al.’s (2000) results. We are currently
investigating whether and how we can differ-
entiate anxiety responses from other types of
responses using phasic and tonic responses.
Even if we assume an anxiety response, the
question remains of whether or not it is an
initial, secondary (conditioning), or mixed
response to low-level chemical exposure.
There are several limitations to this study.
First, because it was a pilot study, the number
of cases and controls was relatively small, and
results need to be conﬁrmed with a larger study.
Then, to ensure a double-blind design, it will
be necessary to have two separate individuals,
one doing the data analysis and the other in
charge of introducing the different substances.
In addition, the observer, the nurse, might have
been able to pick up the smell of some sub-
stances and give unconscious nonverbal cues to
the patient inside the booth. We have since
installed a video camera that allows remote
observation of the patient inside the booth but
have not detected any difference in the results
due to this change. Although the air ﬂow in the
booth was maintained constant and substances
were introduced every time in the same man-
ner, it would be essential to measure (with gas
chromatography) the actual levels reaching the
individuals and ensure that delivery of the sub-
stances is constant through methods such as
those described by Fiedler et al. (2000).
Conclusions
In terms of experimental design, this pilot
study raised the significance of including an
adaptation phase to get stable physiologic
measurements and minimize noise in the
results. This study also brings up questions
regarding the signiﬁcance of an electrodermal
response to low-level chemical substances. Are
we observing an unconscious anxiety response,
or another type of response such as neurogenic
inﬂammation? Other measures such as func-
tional magnetic resonance imaging would cer-
tainly add understanding of the brain regions
involved in the reactivity, but this will require
unique laboratory conditions. Reproducibility
of these results and understanding the patho-
physiologic mechanism should be the next
priorities.
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